Evidence map›Paper›PMID 33205595›Full record

ArticleCancer medicine2021

Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe).

Murat Gultekin, Sertac Ak, Ali Ayhan, Aleksandra Strojna, Andrei Pletnev, Anna Fagotti, Anna Myriam Perrone, B Emre Erzeneoglu, B Esat Temiz, Birthe Lemley and 26 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 5 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 5 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Counting the social, psychological, and economic costs of COVID-19 for cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Predicting psychological distress in advanced ovarian cancer patients during the COVID-19 pandemic.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  10. Article
  11. Article
  12. Measuring reconceptualization and reprioritization during France's first COVID-19-related lockdown in women with and without a history of cancer: an adaptation of the SeiQol-DW and PGI.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Assessment of Cancer Patients' Mental Health during the Coronavirus Pandemic in Serbia.International journal of environmental research and public health · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 15 countries.

Murat GultekinFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.ORCID 0000-0002-4221-4459
Sertac AkStress Assesment and Research Center (STAR, Hacettepe University, Ankara, Turkey.
Ali AyhanFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Baskent University, Ankara, Turkey.
Aleksandra StrojnaDepartment of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
Andrei PletnevDepartment of Gynecologic Oncology, N.N. Alexandrov National Cancer Center of Belarus, Minsk, Belarus.
Anna FagottiFondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
Anna Myriam PerroneSant Orsola-Malpighi Hospital, Bologna, Italy.ORCID 0000-0003-3140-4772
B Emre ErzeneogluFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.
B Esat TemizFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.
Birthe LemleyEuropean Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Burcu SoyakFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.
Cathy HughesOvacome - Ovarian Cancer Support Charity, London, UK.
David CibulaDepartment of Obstetrics and Gynecology, Gynecologic Oncology Center, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Dimitrios HaidopoulosDepartment of Obstetrics and Gynecology, Alexandra Hospital, University of Athens, Athens, Greece.
Donal BrennanDepartment of Gynaecological Oncology, University College Dublin (UCD) School of Medicine, Catherine McAuley Research Centre, Mater University Hospital, Dublin, Ireland.
Edoardo ColaFondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
Elzbieta van der Steen-BanasikRadiotherapy Institute, Arnhem, The Netherlands.
Esra UrkmezEuropean Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Huseyin AkilliFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Baskent University, Ankara, Turkey.
Ignacio ZapardielGynecologic Oncology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Icó TóthEuropean Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Jalid SehouliDepartment of Gynecology with Center for Oncological Surgery, Charité-University Hospital, Berlin, Germany.
Kamil ZalewskiEuropean Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Kiarash BahremandDepartment of Gynaecology, National Institute of Oncology, Budapest, Hungary.
Luis ChivaClinica Universidad de Navarra, Madrid, Spain.
Mansoor Raza MirzaDepartment of Oncology, The Finsen Centre, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark.
Maria PapageorgiouEuropean Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Novak ZoltanDepartment of Gynaecology, National Institute of Oncology, Budapest, Hungary.
Petra AdámkováEuropean Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Philippe MoriceDepartment of Surgery, Institute Gustave Roussy, Villejuif, France.
Sonia Garrido-MallachGynecologic Oncology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Utku AkgorFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.
Vasilis TheodoulidisDepartment of Obstetrics and Gynecology, Alexandra Hospital, University of Athens, Athens, Greece.
Zafer ArikFaculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey.
Karina D SteffensenEuropean Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Christina FotopoulouDepartment of Gynecology, Imperial College London, NHS Trust London, London, UK.
European Society of Gynaecological Oncology · CHHacettepe University · TRBaşkent University · TRHospital Universitario La Paz · ESNational and Kapodistrian University of Athens · GRNational Institute of Oncology · HUUniversità Cattolica del Sacro Cuore · ITBarts Health NHS Trust · GBCharité - Universitätsmedizin Berlin · DECharles University · CZClinica Universidad de Navarra · ESCopenhagen University Hospital · DKImperial College London · GBInstitut Gustave Roussy · FRIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITN.N. Alexandrov National Cancer Centre · BYOvarian Cancer Action · GBPomeranian Medical University · PLRadiotherapiegroep · NLUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of the COVID-19 pandemic on European gynaecological cancer patients under active treatment or follow-up has not been documented. We sought to capture the patient perceptions of the COVID-19 implications and the worldwide imposed treatment modifications.

methodsA patient survey was conducted in 16 European countries, using a new COVID-19-related questionnaire, developed by ENGAGe and the Hospital Anxiety & Depression Scale questionnaire (HADS). The survey was promoted by national patient advocacy groups and charitable organisations.

findingsWe collected 1388 forms; 592 online and 796 hard-copy (May, 2020). We excluded 137 due to missing data. Median patients' age was 55 years (range: 18-89), 54.7% had ovarian cancer and 15.5% were preoperative. Even though 73.2% of patients named cancer as a risk factor for COVID-19, only 17.5% were more afraid of COVID-19 than their cancer condition, with advanced age (>70 years) as the only significant risk factor for that. Overall, 71% were concerned about cancer progression if their treatment/follow-up was cancelled/postponed. Most patients (64%) had their care continued as planned, but 72.3% (n = 892) said that they received no information around overall COVID-19 infection rates of patients and staff, testing or measures taken in their treating hospital. Mean HADS Anxiety and Depression Scores were 8.8 (range: 5.3-12) and 8.1 (range: 3.8-13.4), respectively. Multivariate analysis identified high HADS-depression scores, having experienced modifications of care due to the pandemic and concern about not being able to visit their doctor as independent predictors of patients' anxiety.

interpretationGynaecological cancer patients expressed significant anxiety about progression of their disease due to modifications of care related to the COVID-19 pandemic and wished to pursue their treatment as planned despite the associated risks. Healthcare professionals should take this into consideration when making decisions that impact patients care in times of crisis and to develop initiatives to improve patients' communication and education.

Indexed as

Surveys and QuestionnairesAdolescentAdultAgedAged, 80 and overAnxietyCOVID-19DepressionEuropeFearFemaleGenital Neoplasms, FemaleHumansMiddle AgedPandemicsSARS-CoV-2anxietycancerCOVID-19depressionEUexpectationgynaecologic oncologypatientsperspectives

Identifiers

PMID33205595
PMCPMC7753798
OpenAlexW3100446156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.